"Designing Growth Strategies is in our DNA"

Antipsychotic Drugs Market Size, Share and Industry Analysis, By Disease (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Others), By Therapeutic Class (First Generation, Second Generation, Third Generation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast 2019-2026

Region : Global | Format: PDF | Report ID: FBI101390

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version
COVID-19 Cover

We are in process of revamping Antipsychotic Drugs Market with respect to COVID-19 Impact.

Inquire before buying

There is an ever-increasing demand for antipsychotic drugs with greater efficacy and lesser adverse reactions for the treatment of major psychotic disorders including schizophrenia, bipolar disorder, unipolar depression, and other psychotic disorders. Among disease segment, the largest global market share was attributed to schizophrenia in 2018. The large unmet need for new and advanced treatment options of psychotic disorders, with an aim to reduce the adverse effects of antipsychotic drugs on the individuals and greater awareness, has been instrumental in the development and introduction of antipsychotic drugs.


Market players are constantly focusing on R&D to improve the efficiency and safety of antipsychotic drugs, as well as improve efficiency and outcomes of the treatment in the patient population. The usage of second-generation anti-psychotic drugs is currently one of the most attractive drug classes in the global antipsychotic therapeutic market.


Request a sample to learn more about this report.


Key Market Drivers


"Increasing Awareness Regarding Psychotic Disorders and New Product Launches to Boost Market Growth"


A significant proportion of patient pool globally is suffering from psychotic disorders including the various types of schizophrenia, bipolar disorder, and unipolar depression or major depressive disorder. The efficiency of drugs in the treatment of these psychotic disorders is of utmost importance, and this has led to increasing demand for safer and highly efficient drugs for the treatment of psychotic disorders. According to the American Psychiatric Association (APA), an estimated one in twenty four individuals are anticipated to suffer from serious mental disorders which includes serious psychotic disorders.


Also, there is a increasing awareness amongst individuals regarding the effective treatment of psychotic disorders. These factors, combined with the introduction of new antipsychotic drugs based on innovative R&D by market players, are some of the major factors driving the market sales in 2018. However, the occurrence of adverse reactions among the patient population attributed to the usage of antipsychotic drugs and the relapses of acute psychotic episodes, are some of the factors limiting the adoption of antipsychotic drugs in the global market.


Market Segmentation


Based on the disease, The antipsychotic therapeutic market segments include schizophrenia, bipolar disorder, unipolar depression, dementia, and others. The schizophrenia segment dominated the antipsychotic drugs market share in 2018. The segment accounted for 45.2% share of the market in 2018. Based on therapeutic class, the global market segments include first generation, second generation, and third generation. Based on distribution channel, the global market segments include hospital pharmacies, retail pharmacies, online pharmacies, and others.


To know how our report can help streamline your business, Speak to Analyst


Regional Analysis


"An increasing number of patients undergoing treatment for psychotic disorders is fueling the demand for antipsychotic drugs in North America"


There is a large patient pool in emerging countries including China, India, and other South-east Asian countries suffering from various psychotic disorders. However, there is a greater adoption of second generation antipsychotic drugs over the first generation antipsychotic drugs due to greater awareness and increasing healthcare expenditure. In North America, there is a higher adoption of advanced antipsychotic drugs among healthcare providers in the U.S., and the increasing number of patients are undergoing treatment for psychotic disorders in the country.


This, combined with the rising preference for highly advanced and safe antipsychotic drugs in the treatment of schizophrenia, and other psychotic diseases in the U.S., are propelling the growth of the market in North America. The antipsychotic therapeutic market in North America was valued at USD 9,307.3 Million in 2018. Europe is anticipated to be the second most dominant market after North America. The Asia Pacific is projected to demonstrate a comparatively higher CAGR during forecast period, owing to rising patient pool undergoing treatment for psychotic disorders. The market in Middle East & Africa, and Latin America accounted for a comparatively small share of the market in 2018.


North America Antipsychotic Drugs Market Size, 2018

To get more information on the regional analysis of this market, Request a sample


Key Market Players


"H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., and Janssen Pharmaceuticals, Inc., dominated the global market in 2018"


The global antipsychotic therapeutic market is a semi-consolidated market with the top three players coupled with some other key players accounting for a significant share of the market in 2018. A well-established brand presence in the market, combined with a strong distribution channel and persistent R&D, has been instrumental in the dominance of these players, which augments the antipsychotic drugs market growth. However, other market players are expanding their portfolio of antipsychotic drugs, and are focusing on the expansion of geographic presence, their pipelines and strengthening their distribution channel, and are expected to gain market share during the forecast period.


Report Coverage 


According to the American Psychiatric Association (APA), one in every 24 individuals in the U.S., an estimated 4.1%, suffer from a serious mental illness. This includes such as schizophrenia, bipolar disorder, and unipolar depression. This large patient pool suffering from psychiatric illnesses, combined with greater awareness of psychotic disorders, and the increasing efficacy of the recent antipsychotic drugs, are leading to rising demand for antipsychotic drugs globally.


The introduction of new products in the antipsychotic drugs market report, along with an increasing number of patients undergoing treatment for psychotic disorders globally are projected to further augment the demand for antipsychotic drugs during the forecast period.


The report provides qualitative and quantitative insights on the antipsychotic drugs industry trends and detailed analysis of market size and growth rate for all possible segments in the market. The antipsychotic therapeutic market segments include disease, drug classification, distribution channel, and geography. On the basis of the disease, the market segments include schizophrenia, bipolar disorder, unipolar depression, dementia, and others.


To gain extensive insights into the market, Request for Customization


Based on therapeutic class, the global antipsychotic drugs industry is segmented into first generation, second generation, and third generation. Based on distribution channel, the antipsychotic therapeutic market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Geographically, the global market is segmented into five major regions, which are North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The regions are further categorized into countries.


Along with this, the report - antipsychotic drugs market includes market dynamics and competitive landscape. Various key insights provided in the report are the overview of prevalence of psychiatric disorders by key regions, pipeline analysis, key industry developments, new product launches, analysis of the cost and burden of mental health disorders, analysis of antipsychotics in treatment of dementia, analysis of first generation antipsychotics versus second & third generation antipsychotics, overview of R&D initiatives, and others.


Segmentation


























 ATTRIBUTE


 DETAILS

By Disease




  • Schizophrenia

  • Bipolar Disorder

  • Unipolar Depression

  • Dementia

  • Others



By Therapeutic Class




  • First Generation

  • Second Generation

  • Third Generation



By Distribution Channel




  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

  • Others



By Geography




  • North America (the USA and Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico and Rest of Latin America)

  • Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)



Antipsychotic Drugs Market Players



  • H. Lundbeck A/S

  • Otsuka Pharmaceutical Co., Ltd.

  • Janssen Pharmaceuticals, Inc.

  • Eli Lilly and Company

  • AstraZeneca

  • ALLERGAN

  • Vanda Pharmaceuticals Inc. 

  • Sumitomo Dainippon Pharma Co., Ltd.

  • Alkermes plc

  • Pfizer Inc.

  • Bristol-Myers Squibb Company

  • Other Prominent Players


Key Industry Developments



  • In July 2018, the new antipsychotic drug called Perseris, an extended-release injectable form of risperidone from Indivior PLC won the FDA approval for the treatment of schizophrenia

  • In May 2019, the FDA approved ALLERGAN’s antipsychotic drug Vraylar for the treatment of depression in adults diagnosed with bipolar disorder, which makes the drug the first ever approved to treat the full spectrum of symptoms in bipolar I

  • In April 2018, Otsuka Pharmaceutical Co., Ltd. announced the launch of REXULTI tablets for the treatment of schizophrenia in Japan


Frequently Asked Questions

Fortune Business Insights says that the market was valued at USD 14.96 Billion in 2018 and is projected to reach USD 20.54 Billion by 2026.

In 2018, the market was valued at USD 14.96 Billion.

Growing at a CAGR of 4.0%, the market will exhibit steady growth in the forecast period (2019-2026)

Schizophrenia segment is expected to be the leading segment in this market during the forecast period.

Increased regarding psychotic disorders and efficient drug launches will drive the growth of the market.

H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., and Janssen Pharmaceuticals, Inc. are the top players in the market.

North America is expected to hold the highest market share in the market.

Increased awareness, increasing prevalence of psychotic disorders, R&D of antipsychotics drugs of advanced generations and new product launches such as long acting injectable (LAIs) would drive the adoption.

Adoption of advanced antipsychotics drugs, novel modes of drug delivery, launches of long acting injectable (LAIs), advances in R&D leading to significant reduction of extrapyramidal motor control disabilities, and increased awareness amongst owners are the hyper-market trends of antipsychotic drugs.

Antipsychotic Drugs Market Size, Share and Global Industry Trend Forecast till 2026
  • Sep, 2019
  • 2018
  • 2015-2017
  • 119

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Healthcare Clients

Logo_Merck_KGaA_2015
DUPONT
Intuitive_Surgical_logo
SUANFARMA
DAEWOONG

Related Reports

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X